一、募集资金基本情况 （一）实际募集资金金额及资金到位情况 2019 年 10 月 12 日，经中国证券监督管理委员会"证监许可[2019]1886 号" 《关于同意宁波长阳科技股份有限公司首次公开发行股票注册的批复》同意注册， 公司首次向社会公开发行人民币普通股股票 70,642,200.00 股，每股面值 1.00 元， 每股发行价格 13.71 元，募集资金总额为人民币 968,504,562.00 元，扣除发行费 用人民币 111,786,359.20 元（不含增值税进项税），实际募集资金净额为人民币 856,718,202.80 元。上述募集资金于 2019 年 10 月 30 日到账，募集资金到位情况 业经立信会计师事务所（特殊普通合伙）验证，并出具了信会师报字[2019]第 ZA15720 号《验资报告》。 证券代码：688299 证券简称：长阳科技 公告编号：2025-040 宁波长阳科技股份有限公司 2025年半年度募集资金存放、管理与实际使用情况的专项报 告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任 ...

证券代码：688299 证券简称：长阳科技 公告编号：2025-039 宁波长阳科技股份有限公司 第四届监事会第五次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 2025 年 8 月 25 日，宁波长阳科技股份有限公司（以下简称"公司"）第四届 监事会第五次会议（下称"本次会议"）在公司会议室以现场方式召开。本次会议 由王云主持，会议应到监事 3 名，实到监事 3 名，本次会议的召集、召开符合 《公司法》等法律、法规、规范性文件和《宁波长阳科技股份有限公司章程》、 《宁波长阳科技股份有限公司监事会议事规则》的有关规定。 二、监事会会议审议情况 经与会监事审议，做出以下决议： （一）审议通过《关于公司 2025 年半年度报告及摘要的议案》 监事会在全面审阅公司 2025 年半年度报告后，发表意见如下： 具体内容详见本公司同日在上海证券交易所网站（www.sse.com.cn）披露的 《公司2025年半年度报告及摘要》。 （二）审议通过《关于公司2025年半年度募集资金存放、管理与实际使 ...

Investment Rating - The report maintains an investment rating of "B" for the biopharmaceutical industry, indicating that it is expected to outperform the market [1][3]. Core Insights - The report highlights that tumor immunotherapy (IO) is a cornerstone treatment for non-small cell lung cancer (NSCLC), with next-generation IO therapies based on PD-1/L1 monoclonal antibodies showing promise when combined with VEGF, IL-2, ADC, and CTLA-4 to overcome immune resistance and improve survival rates [3][4]. - PD-1/VEGF dual antibodies have demonstrated significant clinical benefits in first-line progression-free survival (PFS) and overall survival (OS) settings, while PD-L1 ADCs offer new options for immune-resistant cases [3][4]. - The report notes that the combination of PD-1/VEGF dual antibodies with chemotherapy has outperformed PD-1 monoclonal antibodies combined with chemotherapy in clinical trials [3][4]. Summary by Sections Tumor Immunotherapy Developments - The report discusses the efficacy of various ADC drugs in NSCLC, including TROP2, EGFR×HER3, and PD-L1 ADCs, which have shown outstanding results [3]. - PD-1/VEGF dual antibodies have reached PFS endpoints in clinical trials for squamous NSCLC, with an overall response rate (ORR) of 71.4% and a median duration of response (mDOR) of 12.7 months [4]. Clinical Trial Results - In first-line PD-L1 positive NSCLC, the ORR for the 707 single-agent treatment was 70.8%, while the combination with chemotherapy yielded an ORR of 58.3% for non-squamous and 81.3% for squamous NSCLC [4]. - The report also highlights the significant OS benefits observed with the PD-1/IL-2α-bias dual antibody fusion protein IBI363 in previously treated squamous NSCLC, achieving a median OS of 15.3 months [5]. Emerging Therapies - The PD-L1 ADC HLX43 has shown an ORR of 31.9% in CPI-treated NSCLC, with a notable 47.4% ORR in the EGFR wild-type non-squamous NSCLC subgroup [6]. - The report emphasizes the potential of the PD-1/VEGF/CTLA-4 triple antibody CS2009, which has demonstrated anti-tumor activity in early clinical trials [6].

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The chlor-alkali industry is experiencing a recovery in profitability, driven by a tightening supply of glyphosate and glufosinate, leading to price increases [4][20] - The "anti-involution" policy is expected to be a key focus in 2025 and beyond, aiming to optimize the competitive landscape in the chemical industry [26] Summary by Sections Industry Trends - The chemical industry index outperformed the CSI 300 index by 1.1% this week, with 76.7% of the 545 tracked stocks showing weekly gains [17] - The average price of glyphosate increased to 26,399 CNY/ton, a rise of 0.37% from the previous week, while glufosinate also saw a price increase [21][22] Key Products Tracking - Urea and potassium chloride prices have risen, while phosphorite and phosphates remain stable [52] - The average price of urea reached 1,780 CNY/ton, up 0.62% from the previous week, driven by improved market sentiment [52][54] Recommended and Beneficiary Stocks - Recommended stocks include leading chemical companies such as Wanhua Chemical, Hualu Hengsheng, and Hengli Petrochemical [6][26] - Beneficiary stocks include companies like Jiangshan Co., Ltd. and Hebei New Chemical Materials [24][27]

金融界消息 截至2025年8月8日收盘，长阳科技（688299）报收于17.38元，下跌1.42%，换手率4.57%， 成交量13.14万手，成交金额2.29亿元。 天眼查商业履历信息显示，宁波长阳科技股份有限公司，成立于2010年，位于宁波市，是一家以从事化 学原料和化学制品制造业为主的企业。企业注册资本28739.2894万人民币，实缴资本1844.6万人民币。 公司法定代表人为金亚东。 通过天眼查大数据分析，宁波长阳科技股份有限公司共对外投资了7家企业，参与招投标项目15次，知 识产权方面有商标信息12条，专利信息369条，此外企业还拥有行政许可12个。 来源：金融界 资金流向方面，今日主力资金净流出3035.52万元，占比成交额13.27%。其中，超大单净流出941.84万 元、占成交额4.12%，大单净流出2093.68万元、占成交额9.15%，中单净流出流入2039.82万元、占成交 额8.92%，小单净流入995.71万元、占成交额4.35%。 长阳科技最新一期业绩显示，截至2025一季报，公司营业总收入2.67亿元、同比减少14.97%，归属净利 润1416.24万元，同比增长72.02%，扣 ...

专题：专题|2024年度A股董秘数据报告：1144位董秘年薪超百万 占比超21% 数据显示，截止7月29日，A股市场共有5817家上市公司。作为上市公司核心管理层关键成员，财务总 监CFO不仅需要确保公司财务稳健、资金高效运转，更需要从财务视角为公司的战略制定提供支撑，其 能力与决策直接影响公司的财务健康、战略成败、资本市场形象乃至生存风险。据2024年年报显示，去 年A股CFO（财务总监、财务负责人等）薪酬合计达42.43亿元，平均薪酬76.03万元。 分行业来看，光学光电子行业信息完备的上市公司CFO共有69位，2024年CFO平均薪酬为79.94万元， 在124个申万一级行业中排名第66位，CFO薪资水平处于行业中游。此外， 2024年光学光电子行业董秘 平均薪资水平相较上年上升5.69万元，薪酬增幅在124个申万一级行业中排名第33位，处于行业前列。 从光学光电子行业的CFO薪酬分布角度来看，69位CFO中有35位的薪酬水平处于50万元到100万元之 间，占比超五成。此外，光学光电子行业中薪酬超100万元的CFO为14位，占比超两成。其中，薪酬最 高的CFO为冠捷科技张强、莱宝高科梁新辉，其薪资分别为 ...

Core Viewpoint - The optical enhancement film market is experiencing growth driven by increasing demand for display quality in electronic products such as smartphones, tablets, and laptops, with the market size in China expected to reach 6.57 billion yuan in 2024, a year-on-year increase of 10.1% [1][14]. Group 1: Industry Overview - Optical enhancement film, also known as prism film or BEF, is a crucial component in LCD backlight modules, enhancing display brightness and controlling viewing angles [3][14]. - The film is widely used in various electronic devices, including smartphones, LCD TVs, digital cameras, and automotive displays [3][6]. - The industry is supported by a growing demand in emerging applications such as automotive displays and smart home devices [1][14]. Group 2: Market Dynamics - The optical enhancement film market in China is projected to grow from 28 billion yuan in 2015 to 56.6 billion yuan in 2024, reflecting a robust demand driven by the booming downstream panel industry [12]. - The smartphone sector is a significant end-user of optical enhancement films, with China's smartphone shipments expected to reach 286 million units in 2024, a year-on-year increase of 5.54% [10]. Group 3: Competitive Landscape - The optical enhancement film industry in China is highly competitive, with key players including Ningbo Jizhi Technology Co., Ltd., Ningbo Changyang Technology Co., Ltd., and Daoming Optics Co., Ltd. [16][17]. - Companies are under pressure to improve product quality and innovate to meet consumer demands [16]. Group 4: Industry Trends - The industry is moving towards thinner products to meet the demand for lightweight and high-definition displays, with ultra-thin optical enhancement films being developed [21]. - There is a trend towards functional composite films that integrate multiple optical functions to reduce costs and improve assembly efficiency [22]. - Environmental considerations are becoming increasingly important, with a shift towards green production technologies and recycling practices in the optical enhancement film sector [24].

Market Overview - The Shanghai Composite Index is at 3568.96 points with a change of 0.25% [1] - The total trading volume of A-shares is 11803.88 billion yuan [1] Technical Analysis - 42 A-shares have seen their 5-day moving average cross below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Sifang Precision (300468) with a distance of -1.65% [1] - Zhongyou Capital (000617) with a distance of -1.06% [1] - Langxin Group (300682) with a distance of -0.89% [1] Individual Stock Performance - Sifang Precision (300468) has decreased by 1.63% today with a turnover rate of 5.43% [1] - Zhongyou Capital (000617) has decreased by 3.65% today with a turnover rate of 1.65% [1] - Langxin Group (300682) has decreased by 0.86% today with a turnover rate of 1.91% [1] - Other stocks with notable performance include: - China Life Insurance (601319) with a slight increase of 0.12% [1] - Haosen Intelligent (688529) with an increase of 1.31% [1] - Donglai Technology (688129) with an increase of 1.88% [1] Additional Stock Data - Stocks showing a decrease in their 5-day moving average compared to the 10-day moving average include: - Mengjie (002397) down by 1.39% [1] - Greenland Holdings (600606) down by 0.53% [1] - Lida Xin (605365) down by 0.88% [1] - Stocks with minor changes include: - Jiemai (300868) down by 0.23% [2] - Lianchuang Electronics (002036) up by 0.19% [2] - ST Panda (600599) up by 0.26% [2]

Market Overview - The Shanghai Composite Index closed at 3567.02 points, with a change of 0.20% [1] - The total trading volume of A-shares reached 932.32 billion yuan [1] Technical Analysis - A total of 45 A-shares experienced a death cross, where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Sifang Jingchuang (300468) with a distance of -1.64% - Zhongyou Capital (000617) with a distance of -1.04% - Langxin Group (300682) with a distance of -0.94% [1] Individual Stock Performance - Sifang Jingchuang (300468) saw a decline of 1.58% with a trading turnover of 4.30% [1] - Zhongyou Capital (000617) decreased by 3.42% with a turnover of 1.28% [1] - Langxin Group (300682) fell by 1.37% with a turnover of 1.64% [1] - Other notable stocks include: - China Life Insurance (601319) increased by 0.37% [1] - Haosen Intelligent (688529) rose by 0.71% [1] - Donglai Technology (688129) increased by 1.25% [1] Additional Stock Movements - Stocks with minor declines include: - Huatai Wine Industry (000995) down by 1.31% [1] - Changyang Technology (688299) down by 0.22% [1] - Dream Jie's (002397) decline of 1.39% [1] - Stocks with slight increases include: - Matrix Technology (301299) up by 1.15% [2] - Lianxin Electronics (002036) down by 0.47% [2]

Market Overview - The Shanghai Composite Index is at 3568.16 points, with a change of 0.23% [1] - The total trading volume of A-shares is 697.23 billion yuan [1] Technical Analysis - 49 A-shares have seen their 5-day moving average cross below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Sifang Precision (300468) at -1.60% - Langxin Group (300682) at -0.99% - Zhongyou Capital (000617) at -0.91% [1] Individual Stock Performance - Sifang Precision (300468): Today's change is -1.11%, with a latest price of 37.52 yuan, which is -8.04% from the 10-day moving average [1] - Langxin Group (300682): Today's change is -1.88%, with a latest price of 19.29 yuan, which is -6.20% from the 10-day moving average [1] - Zhongyou Capital (000617): Today's change is -2.05%, with a latest price of 8.59 yuan, which is -4.96% from the 10-day moving average [1] - Other stocks with notable performance include: - China Reinsurance (601319): +0.12%, latest price 8.17 yuan, -2.73% from the 10-day moving average [1] - Haosen Intelligent (688529): +0.76%, latest price 19.97 yuan, -0.99% from the 10-day moving average [1] - Huangtai Liquor (000995): -1.52%, latest price 14.29 yuan, -3.99% from the 10-day moving average [1]